M&A Deal Summary

Sun Pharma Acquires Ranbaxy Laboratories

On April 4, 2014, Sun Pharma acquired life science company Ranbaxy Laboratories from Daiichi Sankyo for 4.0B USD

Acquisition Highlights
  • This is Sun Pharma’s 4th transaction in the Life Science sector.
  • This is Sun Pharma’s largest (disclosed) transaction.
  • This is Sun Pharma’s 4th transaction in India.

M&A Deal Summary
Date 2014-04-04
Target Ranbaxy Laboratories
Sector Life Science
Buyer(s) Sun Pharma
Sellers(s) Daiichi Sankyo
Deal Type Divestiture
Deal Value 4.0B USD
Advisor(s) ICICI Securities (Financial)
Luthra & Luthra
Amarchand & Mangaldas & Suresh A. Shroff & Co. (Legal)

Target

Ranbaxy Laboratories

New Delhi, India
Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed and emerging 4 markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sun Pharma

Mumbai, India
Category Company
Founded 1983
Sector Life Science
Employees37,000
Revenue 477.6B INR (2024)
DESCRIPTION

Sun Pharma is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores, and gift/specialty stores. Sun Pharma was founded in 1983 and is based in Mumbai, India.

DEAL STATS #
Overall 8 of 14
Sector (Life Science) 4 of 9
Type (Divestiture) 1 of 2
Country (India) 4 of 4
Year (2014) 1 of 2
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-20 DUSA Pharmaceuticals

Wilmington, Massachusetts, United States

DUSA Pharmaceuticals, Inc.® is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator.

Buy $230M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-16 Pharmalucence

Bedford, Massachusetts, United States

Pharmalucence, Inc.manufacturer of human injectable pharmaceuticals.We provide contract and private label formulation development and manufacturing services of parenteral products in either liquid or lyophilized form.

Buy -

Seller(S) 1

SELLER

Daiichi Sankyo

Tokyo, Japan
Category Company
Founded 1899
Sector Life Science
Employees18,726
Revenue 1.60T JPY (2024)
DESCRIPTION

Daiichi Sankyo established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals. Daiichi Sankyo was incorporated in 1899 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 4
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 4
Country (India) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-28 Plexxikon

Berkeley, California, United States

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease.

Buy $805M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-28 Ambit Biosciences

San Diego, California, United States

Ambit Biosciences Corp. is a biotechnology company focused on oncology; provides drug discovery services to the pharmaceutical industry.

Buy $315M
Mergr

Product

Company

Legal